Verrica Pharmaceuticals Inc. Financing Cash Flow
Verrica Pharmaceuticals Inc. (VRCA) reported Financing Cash Flow of -$246.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- Verrica Pharmaceuticals Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$126.00K.
- Verrica Pharmaceuticals Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$120.00K.
- Verrica Pharmaceuticals Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $13.64M, a 65.40% decline year-over-year.
- Verrica Pharmaceuticals Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$3.98M.
- Verrica Pharmaceuticals Inc. net cash provided by (used in) financing activities for fiscal 2025 was $1.45M, a 96.17% decline from fiscal 2024.
- Verrica Pharmaceuticals Inc. net cash provided by (used in) financing activities for fiscal 2024 was $37.73M, a 49.16% decline from fiscal 2023.
- Verrica Pharmaceuticals Inc. net cash provided by (used in) financing activities for fiscal 2023 was $74.21M.
- Verrica Pharmaceuticals Inc. net cash provided by (used in) financing activities for fiscal 2022 was -$16.87M, a 150.14% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$126.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$246.00K 10-Q · filed 2026-08-06 | $13.39M derived: sum of 3 quarters · filed 2026-08-06 | $9.41M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$120.00K 10-Q · filed 2026-05-12 | $13.52M derived: sum of 2 quarters · filed 2026-05-12 | $9.54M derived: sum of 3 quarters · filed 2026-05-12 | $5.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $13.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $9.66M derived: sum of 2 quarters · filed 2026-03-11 | $5.50M derived: sum of 3 quarters · filed 2026-08-06 | $1.45M 10-K · filed 2026-03-11 |
| 2025-09-30 | -$3.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$8.14M derived: sum of 2 quarters · filed 2026-08-06 | -$12.20M 10-Q · filed 2025-11-14 | $27.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$4.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$8.21M 10-Q · filed 2026-08-06 | $31.21M derived: sum of 3 quarters · filed 2026-08-06 | $30.82M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$4.06M 10-Q · filed 2026-05-12 | $35.37M derived: sum of 2 quarters · filed 2026-05-12 | $34.97M derived: sum of 3 quarters · filed 2026-05-12 | $34.33M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $39.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $39.03M derived: sum of 2 quarters · filed 2026-03-11 | $38.39M derived: sum of 3 quarters · filed 2026-03-11 | $37.73M 10-K · filed 2026-03-11 |
| 2024-09-30 | -$397.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$1.04M derived: sum of 2 quarters · filed 2025-11-14 | -$1.70M 10-Q · filed 2025-11-14 | -$1.73M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$640.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$1.30M 10-Q · filed 2025-08-12 | -$1.33M derived: sum of 3 quarters · filed 2025-08-12 | $42.72M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$661.00K 10-Q · filed 2025-05-13 | -$688.00K derived: sum of 2 quarters · filed 2025-05-13 | $43.36M derived: sum of 3 quarters · filed 2025-05-13 | $43.27M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $44.02M derived: sum of 2 quarters · filed 2025-03-11 | $43.93M derived: sum of 3 quarters · filed 2025-03-11 | $74.21M 10-K · filed 2025-03-11 |
| 2023-09-30 | $44.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $43.96M derived: sum of 2 quarters · filed 2024-11-05 | $74.24M 10-Q · filed 2024-11-05 | $74.24M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$84.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $30.20M 10-Q · filed 2024-08-14 | $30.20M derived: sum of 3 quarters · filed 2024-08-14 | $13.35M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $30.28M 10-Q · filed 2024-05-13 | $30.28M derived: sum of 2 quarters · filed 2024-05-13 | $13.43M derived: sum of 3 quarters · filed 2024-05-13 | $13.43M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$16.85M derived: sum of 2 quarters · filed 2024-02-29 | -$16.85M derived: sum of 3 quarters · filed 2024-02-29 | -$16.87M 10-K · filed 2024-02-29 |
| 2022-09-30 | -$16.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$16.85M derived: sum of 2 quarters · filed 2023-11-09 | -$16.87M 10-Q · filed 2023-11-09 | -$16.87M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$19.00K 10-Q · filed 2023-08-08 | -$22.00K derived: sum of 3 quarters · filed 2023-08-08 | $21.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$18.00K 10-Q · filed 2023-05-09 | -$21.00K derived: sum of 2 quarters · filed 2023-05-09 | $22.00K derived: sum of 3 quarters · filed 2023-05-09 | $263.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $40.00K derived: sum of 2 quarters · filed 2023-03-06 | $281.00K derived: sum of 3 quarters · filed 2023-03-06 | $33.65M 10-K · filed 2023-03-06 |
| 2021-09-30 | $43.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $284.00K derived: sum of 2 quarters · filed 2022-11-07 | $33.65M 10-Q · filed 2022-11-07 | $34.09M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $241.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $33.61M 10-Q · filed 2022-08-11 | $34.05M derived: sum of 3 quarters · filed 2022-08-11 | $34.05M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $33.37M 10-Q · filed 2022-05-09 | $33.81M derived: sum of 2 quarters · filed 2022-05-09 | $33.81M derived: sum of 3 quarters · filed 2022-05-09 | $33.72M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $445.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $445.00K derived: sum of 2 quarters · filed 2022-03-02 | $355.00K derived: sum of 3 quarters · filed 2022-03-02 | $35.23M 10-K · filed 2022-03-02 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$90.00K derived: sum of 2 quarters · filed 2021-11-12 | $34.79M 10-Q · filed 2021-11-12 | $34.99M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | -$90.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $34.79M 10-Q · filed 2021-08-10 | $34.99M derived: sum of 3 quarters · filed 2021-08-10 | $34.99M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $34.88M 10-Q · filed 2021-05-07 | $35.08M derived: sum of 2 quarters · filed 2021-05-07 | $35.09M derived: sum of 3 quarters · filed 2021-05-07 | $35.30M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | $204.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | $208.00K derived: sum of 2 quarters · filed 2021-03-17 | $420.00K derived: sum of 3 quarters · filed 2021-03-17 | $423.00K 10-K · filed 2021-03-17 |
| 2019-09-30 | $4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $216.00K derived: sum of 2 quarters · filed 2020-11-09 | $219.00K 10-Q · filed 2020-11-09 | $228.00K derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $212.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $215.00K 10-Q · filed 2020-08-05 | $224.00K derived: sum of 3 quarters · filed 2020-08-05 | -$840.00K derived: sum of 4 quarters · filed 2020-08-05 |
| 2019-03-31 | $3.00K 10-Q · filed 2020-05-07 | $12.00K derived: sum of 2 quarters · filed 2020-05-07 | -$1.05M derived: sum of 3 quarters · filed 2020-05-07 | $78.39M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | -$1.05M derived: sum of 2 quarters · filed 2020-03-13 | $78.38M derived: sum of 3 quarters · filed 2020-03-13 | $99.38M 10-K · filed 2020-03-13 |
| 2018-09-30 | -$1.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $78.37M derived: sum of 2 quarters · filed 2019-11-06 | $99.37M 10-Q · filed 2019-11-06 | $109.48M derived: sum of 4 quarters · filed 2019-11-06 |
| 2018-06-30 | $79.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $100.43M 10-Q · filed 2019-08-07 | $110.55M derived: sum of 3 quarters · filed 2019-08-07 | $111.51M derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-03-31 | $20.99M 10-Q · filed 2019-05-07 | $31.11M derived: sum of 2 quarters · filed 2019-05-07 | $32.07M derived: sum of 3 quarters · filed 2019-05-07 | |
| 2017-12-31 | $10.11M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $11.08M derived: sum of 2 quarters · filed 2019-03-07 | $12.72M 10-K · filed 2019-03-07 | |
| 2017-09-30 | $965.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $2.60M 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | $1.64M 10-Q · filed 2018-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |